Hereditary Tyrosinemia, Type I Clinical Trial
Official title:
Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin.
The purpose of this study is to verify that pediatric patients, especially those who are not old enough to swallow capsules, accept the taste and palatability of a new suspension.
This is an open, non-randomized, non-controlled, multiple-dose study in 18 pediatric
patients. The treatment period is three days, and during the study the subjects will rate
the taste and palatability of the suspension or (for younger children) their parents will
rate the child´s acceptance of the suspension.
The study consists of a screening period, a 3 day treatment period and a 1 week follow-up
period.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02320084 -
Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care
|
||
Completed |
NCT02750709 -
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
|
Phase 1 | |
Completed |
NCT02750332 -
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
|
Phase 1 | |
Not yet recruiting |
NCT04113772 -
Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine
|
N/A | |
Completed |
NCT02750345 -
Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
|
Phase 1 | |
Completed |
NCT02323529 -
Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1
|
Phase 3 | |
Recruiting |
NCT06227429 -
A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients
|
||
Recruiting |
NCT03446586 -
Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)
|